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Background: Survival in malignant cutaneous melanoma has improved but increasing
survival will result in an increased likelihood of the occurrence of second primary cancers
(SPCs). SPCs may adversely interfere with survival. We quantiﬁed survival in patients with
different types of SPCs, in comparison to known poor prognostic indicators of metastatic
disease.
Methods: Data for melanoma and any SPCs were obtained from the Swedish Cancer
Registry for years 2003 through 2015, including clinical TNM classiﬁcation. SPCs were
grouped into three ‘prognostic groups’ based on 5-year relative survival of these cancers as
ﬁrst primary cancer. Kaplan-Meier survival curves were generated and hazard ratios were
estimated using Cox regression, adjusted for a number of variables and treating diagnosis of
SPC as a time-dependent variable.
Results: The total number of ﬁrst melanoma patients was 28,716 followed by 3,202 (11.1%)
SPCs, 1/3 of which had a second melanoma while 2/3 had other SPCs. Among men
diagnosed at age over 70 years, who survived at least 10 years, 31.4% had SPC. HRs
(95% CI) for survival increased systematically from the reference rate of 1.00 (no SPC) to
1.59 (1.35–1.87) with SPC of good prognosis (78.6% of SPCs) to 3.49 (2.58–4.72) of
moderate prognosis (12.0%) and to 7.93 (5.50–11.44) of poor prognosis (9.4%). In patients
without SPC, the HRs increased to 2.62 (2.02–3.39) with any nodal metastases and to 5.88
(4.57–7.57) with any distant metastases compared to patients without local or distant
metastases.
Conclusion: The data showed that SPCs are an increasingly common negative prognostic
factor for melanoma. Future attempts to improve melanoma survival need to target SPCs.
Keywords: melanoma, second cancer, metastasis, prognosis, survival
Introduction
Survival rates among patients with malignant cutaneous melanoma (shortly mela-
noma) have improved in spite of increasing incidence in many countries.1–3 The
improvements in survival have been ascribed to earlier diagnosis of thinner lesions
due to alertness and screening programs, which may have also caused
“overdiagnosis”.1,2,4 It is likely that therapy has also contributed, or will contribute
in the future, although breakthrough successes in immunotherapy are yet to show at
the population level.5,6 Increasing survival will result in an increased likelihood of
the occurrence of second primary cancers (SPCs). SPCs were diagnosed in 13.3%
of melanoma patients in Sweden and these were often found to be the causes of
death.7 Second melanoma is the most common SPC in melanoma patients and the
risk factors may be shared by ﬁrst and second melanoma, including atypical
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cutaneous nevi, fair skin color, light eye color, common
cutaneous nevi, propensity to sunburn and sunbathing
habits, cutaneous freckles, some occupational exposures
and predisposition to high-risk and low-risk melanoma-
related genes.5,7,8 Second primary melanoma is not always
possible to distinguish from a skin metastasis from a pre-
vious melanoma. Family history of cancer X may also
predispose melanoma patients to cancer X as SPC.7
The object of the present article is to highlight the
assumed adverse role of SPCs in melanoma survival. We
posit that any second cancer, including melanoma, is a
burden which may interfere with survival. Moreover, as
most cancers show worse survival than melanoma as ﬁrst
primary cancers, we further posit that they would addi-
tionally worsen melanoma survival as SPCs.
Methods
Cancer data for ﬁrst and any subsequent cancers were
obtained from the Swedish Cancer Registry recording
cancers according to the International Classiﬁcation of
Diseases 7th revision (ICD-7) and later revisions. The
clinical TNM classiﬁcation was started in 2002/2003. We
considered local nodal (N) and distant (M) metastases,
denoted by N+ (N1, N2, N3) or M+ (M1, M2). Because
of the clinical TNM system, many patients had an unde-
ﬁned metastatic status at diagnosis; these were denoted Nx
and Mx and there were included in the analysis but not
listed in the tables. We followed newly diagnosed patients
with melanoma from 1st January 2003 until 31st
December 2015 for diagnosis of any of the 35 different
SPCs including second melanomas. The follow-up for
survival time was terminated at emigration, death, or
31st December 2015, whichever occurred earliest.
Because the novel aspect of the study was to consider
the contribution of SPC to melanoma mortality we con-
sidered overall mortality as the survival end point.
We grouped SPCs into three ‘prognostic groups’ based
on 5-year relative survival of these cancers as ﬁrst primary
cancer:9,10 “good survival” (relative survival >60%)
included cancers in the lip, larynx, anus, breast, cervix,
endometrium, prostate, testis, male genitals, kidney, bladder,
melanoma, skin (squamous cell, SCC), eye, thyroid gland
and endocrine, and Hodgkin lymphoma, hairy cell leuke-
mia, polycythaemia vera, myeloﬁbrosis, chronic and unspe-
ciﬁed lymphatic leukemia; “moderate survival” (40–60%)
included cancers in the remaining upper aerodigestive tract,
salivary glands, small intestine, colorectum, female genitals,
bone and connective tissue, and non-Hodgkin lymphoma,
acute lymphatic leukemia, chronic and unspeciﬁed myeloid
leukemia; “poor survival” (<40%) included cancers in the
stomach, esophagus, liver, pancreas, lung, ovary and ner-
vous system, and myeloma, acute myeloid leukemia and
acute monocytic leukemia.
In this study, SPC diagnoses were considered either by
comparing second melanomas to other SPC, or by asses-
sing survival in prognostic groups of SPC (good, moderate
and poor prognoses). Kaplan-Meier survival curves were
generated for patients with or without diagnoses of SPC.
Hazard ratios (HRs) were estimated with Cox regression,
adjusted for gender, age at diagnosis (≤50, 51–60, 61–70,
71–80, 81–90 and ≥91years old), year of diagnosis (≤2005,
2006–2010 and 2011–2015), tumor size (T1, T2, T3, T4
and others) and histology (superﬁcial spreading, nodular,
lentigo maligna and other melanomas) of the ﬁrst mela-
noma (see Supplementary Table 1). In the analyses, the
diagnosis of SPC was treated as a time-dependent variable
in order to avoid the immortal time bias.11 For Kaplan-
Meier survival curves, individuals with occurrence of mul-
tiple events (ﬁrst cancer and second cancer diagnosed in
the same year, death occurred in the same year of ﬁrst or
second cancer diagnosis) were deleted (N=4,567).
Analyses related to metastasis were performed among
cases with TNM information. Statistical analyses were
done with R version 3.4, SAS version 9.4 and Stata 15.1.
The study was approved (February 6, 2013) by the
Ethical Committee of Lund University, without require-
ment for informed consent (Dnr 2012/795). Through
advertisements in the major newspapers people were
informed about opting out before the research database
was constructed. The project database is located at
Center for Primary Health Care in Malmö, Sweden.
Results
The total number of ﬁrst melanoma patients was 28,716
and during the follow-up from 2003 to 2015, 3,202
(11.1%) patients developed SPCs, including 1082 second
melanomas and 2120 other SPCs, i.e., 33.8% and 66.2%,
respectively. The number of melanoma patients with a
deﬁned T class was 24,828. Detailed patients characteris-
tics are shown in Supplementary Table 1.
Table 1 shows the numbers and percentages of SPCs in
diagnostic age groups of men and women by minimal survi-
val time after melanoma diagnosis. It showsmodest systema-
tic increases (with a few exceptions) in proportions of second
melanomas and large systematic increases in other SPCs by
increasing age and minimal survival time after ﬁrst
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melanoma diagnosis. For men diagnosed at over 70 years,
second melanoma was found in 5.7%, 7.4% and 7.2% of
patients who survived at least 1, 5 and 10 years, respectively.
For non-melanoma SPC the respective percentages were
14.0%, 20.0% and 24.2%. Among men diagnosed at age
over 70 years who survived at least 10 years only 68.6%
were free from SPC (31.4% had SPC). For women diagnosed
at age over 70 years, secondmelanomawas found in between
2% to 4% of cases but non-melanoma SPCs increased in
minimal survival groups from 10.2, to 13.7 and to 21.0% of
cases. Among women who survived at least 10 years, 76.4%
were free from SPC. Female percentages of SPSs were
always lower than male percentages, except for non-mela-
noma SPCs in those diagnosed below age 51 years.
Kaplan-Meier survival data are shown in Figure 1 for
melanoma without SPC and with second melanoma or
non-melanoma SPC. At the end of the 13-year follow-up,
50% of patients were alive with second melanoma com-
pared to 36% when the SPC was another cancer.
Melanoma survival without SPC was 70%. Compared to
melanoma without SPCs the HR was 1.65 for second
melanoma and 1.82 for non-melanoma SPC.
In Figure 2 survival data are shown for SPCs in prognostic
groups, based on the known survival of these cancers as ﬁrst
primaries. At the end of the 13-year follow-up the survival
probabilities were 46%, 27% and 9% for patients with SPC of
good, moderate and poor prognosis, respectively. The respec-
tive HRs were 1.42, 2.32 and 6.24. Note that second mela-
noma was included in the good prognosis group.
Multivariable Cox survival data are shown in Table 2
for melanoma patients divided into prognostic classes. The
difference to Figure 2 was that patients in Table 2 had no
local or distant metastases (N0/M0) at the ﬁrst melanoma
diagnosis. The reference category included patients with-
out SPC and included 91.3% of the cases considered; good
prognosis 6.9%, moderate prognosis 1.0% and poor prog-
nosis 0.8% of the cases. HRs (95% CI) increased system-
atically from the reference rate to 1.59 (1.35–1.87) with
SPC of good prognosis (78.6% of SPCs) to 3.49 (2.58–
4.72) of moderate prognosis (12.0%) and to 7.93 (5.50–
11.44) of poor prognosis (9.4%). The respective numbers
of deaths were 1494 (reference, 81.2% of all), 207
(11.3%), 57 (3.1%) and 82 (4.5%). The HR of any SPC
was 2.21 (1.93–2.54), accounting for 18.8% of all deaths.
Table 1 Distribution of Second Primary Cancer in Melanoma Patients Depending on Survival Time After First Melanoma Diagnosis
Age at Diagnosis (Years Old) Gender SPC Diagnosis Survived at Least
1 Year 5 Years 10 Years
N % N % N %
≤50 Men No SPC 2602 96.0 1412 94.6 405 92.3
Second Melanoma 67 2.5 47 3.2 22 5.0
Other SPC 42 1.5 33 2.2 12 2.7
Women No SPC 4048 94.5 2251 93.1 733 91.7
Second Melanoma 125 2.9 80 3.3 27 3.4
Other SPC 110 2.6 87 3.6 39 4.9
51–70 Men No SPC 4739 84.5 2295 80.3 609 77.1
Second Melanoma 267 4.8 142 5.0 44 5.6
Other SPC 601 10.7 420 14.7 137 17.3
Women No SPC 4495 89.3 2405 86.8 652 83.7
Second Melanoma 170 3.4 105 3.8 36 4.6
Other SPC 369 7.3 260 9.4 91 11.7
≥71 Men No SPC 3263 80.3 1059 72.6 201 68.6
Second Melanoma 233 5.7 108 7.4 21 7.2
Other SPC 570 14.0 291 20.0 71 24.2
Women No SPC 3180 86.0 1245 82.0 240 76.4
Second Melanoma 141 3.8 65 4.3 8 2.5
Other SPC 378 10.2 208 13.7 66 21.0
Abbreviation: SPC, second primary cancer.
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Multivariable Cox survival data in Table 3 consider
melanoma patients with metastases and SPCs. The refer-
ence category constituted patients without nodal or distant
metastases (N0/M0) or SPC, the same as Table 2. In
patients without SPC, the HRs increased to 2.62 (2.02–
3.39) with N+ and to 5.88 (4.57–7.57) with M+ compared
Su
rv
iv
al
 p
ro
ba
bi
lit
y
SPC type HR(95%CI)
No SPC Ref.
Second melanoma 1.65 (1.36-2.01)
Other SPC 1.82 (1.64-2.03)
Without SPC
Second melanoma
No. at risk
No SPC 24149 16703 9134 4119 840
Second melanoma 0 233 212 121 37
Other SPC 0 474 545 396 110
Years since diagnosis of last cancer*
Figure 1 Survival probability after ﬁrst melanoma diagnosis in patients without SPC, with second melanoma and with non-melanoma SPC. *Last cancer was melanoma for
patients during the time with one single melanoma, and was SPC for those from the time with SPC.
Abbreviation: SPC, second primary cancer.
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SPC prognosis HR(95%CI)
No SPC Ref.
Good 1.42 (1.26-1.60)
Moderate 2.32 (1.86-2.89)
Poor 6.24 (5.05-7.71)
Without SPC
Good prognosc SPC
Poor prognosc SPC
Moderate prognosc SPC
No. at risk
No SPC 24149 16703 9134 4119 840
Good 0 562 623 421 122
Moderate 0 95 88 65 19
Poor 0 50 46 31 6
Years since diagnosis of last cancer*
Figure 2 Survival probability after ﬁrst melanoma diagnosis in patients without SPC and with SPC of good, moderate and poor prognosis. *Last cancer was melanoma for
patients during the time with one single melanoma, and was SPC for those from the time with SPC.
Abbreviation: SPC, second primary cancer.
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to the reference. When SPC was melanoma, the HR was
1.45 (1.15–1.84) in patients with N0/M0, and it increased
to 4.28 (2.37–7.71) with N+ and to 11.61 (6.82–19.74)
with M+. When SPC was non-melanoma, the HR for
patients with N0/M0 was 2.59 (2.21–3.04) and it was
6.82 (3.21–14.48) in patients with M+. Case numbers
were low in all categories of patients with SPC and metas-
tases (N+ or M+).
In addition to HRs, it is relevant to consider the pro-
portions of patients. This is however impeded by the large
number of patients with undeﬁned metastatic status.
Among 22,267 melanoma patients with a deﬁned T class,
195 (0.9%) patients had distant metastases (M+) but many
patients were diagnosed as Mx.
Discussion
Based on the Swedish Cancer Registry we showed that
SPCs are an increasingly common negative prognostic
factor for melanoma and the prognostic consequences of
SPCs could be predicted by their known survival data as
ﬁrst primary cancers. The incidence of melanoma has
vastly increased in Sweden during the past half century
but it is not known how this might have inﬂuenced the
incidence of SPCs.2 SPCs following melanoma were
reported in an earlier Swedish study with a 31-year fol-
low-up from 1958 through 1988; 7.6% of patients were
diagnosed with SPC and of these only 15% were second
melanomas.12 In the present study of 13-year follow-up,
11.1% of patients were diagnosed with SPC and of these 1/
3 were second melanomas. Improving survival may be a
contributing factor for these differences of apparently
increasing proportions of SPCs, but increased reporting
of SPCs to the cancer registry may be the main
explanation.
Around year 2005 the 5-year survival in melanoma was
89% in USA, and in Europe it was a few percent points
lower.1,13 While the US 5-year survival for localized mel-
anoma was 96%, it was only 41% for metastatic
melanoma.13 The importance of distant metastases is
well established as a prognostic indicator but in the present
Table 2 Survival in Melanoma Patients Without Local and Distant Metastases (N0/M0) Depending on Second Primary Cancers of
Different Prognostic Groups
SPC of Different Prognosis No. at Risk No. of Death HR 95% CI P-value
No SPC (ref) 15,436 1494 1.00 – – –
SPC of good prognosis 1162 207 1.59 1.35 1.87 3.12×10−08
SPC of moderate prognosis 177 57 3.49 2.58 4.72 4.75×10−16
SPC of poor prognosis 139 82 7.93 5.50 11.44 1.62×10−28
Any SPC 1478 346 2.21 1.93 2.54 1.54×10−29
Note: Model was adjusted for age at and year of diagnosis, tumor size, gender, histology classiﬁcation.
Abbreviations: SPC, second primary cancer; HR, hazard ratio; CI, conﬁdence interval.
Table 3 Survival in Melanoma Patients Depending on Metastases and Second Primary Cancers
SPC Diagnosis and Metastases No. at Risk No. of Death HR 95% CI P-value
No SPC
N0/M0 (ref) 15,436 1494 1.00 – – –
N+/M0 274 118 2.62 2.02 3.39 2.24×10−13
M+ 313 141 5.88 4.57 7.57 2.92×10−43
Second melanoma
N0/M0 525 75 1.45 1.15 1.84 0.0018
N+/M0 10 5 4.28 2.37 7.71 1.34×10−06
M+ 14 10 11.61 6.82 19.74 1.49×10−19
Other cancer
N0/M0 953 271 2.59 2.21 3.04 5.72×10−32
N+/M0 14 4 1.27 0.38 4.21 0.6955
M+ 9 7 6.82 3.21 14.48 5.73×10−07
Notes: Model was adjusted for age at and year of diagnosis, tumor size, gender, histology classiﬁcation. N+ includes N1, N2 and N3; M+ includes M1 and M2.
Abbreviations: SPC, second primary cancer; HR, hazard ratio; CI, conﬁdence interval.
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study, we show that SPCs are another factor worsening
survival in melanoma, irrespective of the metastatic state.
The survival implications of SPCs have not been consid-
ered earlier with the exception of second or multiple
melanomas.14 We showed that among men diagnosed
with melanoma at age over 70 years, who had survived
at least 10 years, 7.2% were diagnosed with second mel-
anoma, and 24.2% with non-melanoma SPC, thus adding
up to 31.4%. Among women the respective percentage
was 23.5.
These proportions are much higher than those for
patients with metastases. Unfortunately, the Swedish clin-
ical TNM data do not allow assessment of the proportions
of patients diagnosed with metastases (because of the
number of undeﬁned cases, Nx, Mx) but a source using
the Swedish Melanoma Register reported the proportions
for stage 3 (i.e., N+/M0) at 2.3% and stage 4 (i.e., M+) at
0.7%.14 The literature on the proportions of localized and
distant metastases varies widely; e.g., in the US SEER data
they are given as 9.9% and 3.4%, and in the Norwegian
Cancer Registry as 5.0% and 3.2%, respectively.15,16
The effects of multiple melanoma diagnosis on mela-
noma mortality have been shown in the literature.14,17,18
However, limited studies reported how SPC other than
melanoma can inﬂuence survival in melanoma patients.
We showed that the prognostic consequences of SPCs
could be predicted by their known survival data as ﬁrst
primary cancers, in line with recent ﬁndings on benign
hematological neoplasms.19 The poor prognosis group,
affecting around 0.9% (139/15,436) of all melanoma
patients but 4.5% of their deaths, showed an HR of 7.93
and included fatal malignancies such as pancreas, lung,
ovarian and nervous system cancers and myeloma. The
most common SPC was melanoma, constituting 33.8% of
all SPCs in this study of maximally 13 years of follow-up.
The caveat is that the spectrum of SPCs changes over
follow-up time. Table 1 shows that the proportions of
second melanomas modestly increased over the minimal
survival time, while for non-melanoma SPCs the increases
were large. The implication was that second melanomas
were diagnosed relatively early after ﬁrst melanoma as a
consequence of clinical follow-up focusing on the skin.
The alternative reasons are that second melanomas are in
fact metastases from the ﬁrst melanoma, or that the ﬁrst
melanoma had modiﬁed host skin susceptible to second
melanoma, through immunological mechanisms for
example.
The HR for second melanoma in Table 3 was 1.45, in
line with a Swedish study measuring melanoma-speciﬁc
survival (HR 1.48).14 That paper discussed other studies
where no survival disadvantage was observed for patients
with second melanoma. Nevertheless, a recent Norwegian
study reported an HR of 2.67 for patients with second
melanoma.16 An important technical note concerning sur-
vival studies is that they are liable to the immortal time
bias.11 This can be avoided by treating SPCs as a time-
dependent variable, as was done by us and by the above
authors.
While early diagnosis of thin, non-ulcerated lesions
promotes favorable survival in melanoma, what can be
done for prevention or early diagnosis of SPCs at large?
For the prevention of SPC, guidelines of general cancer
prevention are valid because the causes of SPCs for
patients not undergoing chemo-or radiotherapy are
believed to be the same that causes of primary cancers.20
For early detection, medical follow-up for second mela-
noma is a normal dermatological and oncological practice,
which might have contributed to the present large numbers
of second melanomas – close monitoring of the skin as
part of follow-up would increase the likelihood of mela-
noma diagnosis. However, this probably also allows for
earlier diagnosis and less melanoma mortality. Family
history of melanoma should signal vigilance for clinical
follow-up.21,22 Our recent study showed that a family
history of cancer X is a risk factor of second cancer X in
melanoma patients.7 Common SPCs with increased famil-
ial risks in melanoma patients included prostate, breast,
colorectal and squamous cell skin cancers, for which
screening methods would be available.7 It is therefore
important for dermatologists and other health care profes-
sionals performing follow-up to inquire about family his-
tories of cancers other than melanoma. Family history
plays a role also for lung cancer which is probably largely
explained by shared smoking habits.
Strengths and Limitations
This study is based on registered data with practically
complete nationwide coverage of medically diagnosed
cancers, which enables enough power of detection and
provides relatively robust and accurate estimates.
Speciﬁcally, in Swedish Cancer Registry diagnosis of sec-
ond cancer is as rigorous as that for the ﬁrst primary
cancer, which mandatorily requests separate and consistent
tumor notiﬁcations from clinicians and pathologists.
According to an ad hoc study on the accuracy of SPC
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diagnosis in the Swedish Cancer Registry, 98% of them
were observed to be correctly classiﬁed.23 Only one study
reported the effects of SPC on the survival of melanoma,7
but it did not consider diagnosis of SPC as time-dependent
variable, which may generate immortal time bias.
Furthermore, SPCs in our study were analysed based on
the survival as the ﬁrst primary cancer, so it has important
clinical guidance for melanoma management.
Some information related to melanoma survival is not
available in our study, for example the treatment for the
patients, although the primary treatment is surgery. The
maximal follow-up time in the present study was 13 years
(because the TNM classiﬁcation was taken to use in 2003
in the Swedish Cancer Registry) which is probably too
short to gauge the maximal proportions of SPCs. We
predict that the full scope of survival disadvantage by
SPC is yet to be recognized. There is a small but unfortu-
nate group of patients who are struck by both of the
negative predictors, metastases and SPC. However, we
were unable to estimate the exact risk due to the current
numbers of such patients.
Conclusions
In conclusion, we show here that SPCs are an increasingly
common negative prognostic factor for melanoma. Second
melanoma is the most common single SPC and early
detection of suspicious lesions can save lives but requires
rigorous monitoring of skin and lymph nodes. Family
history is a risk factor for many SPCs, in addition to
melanoma, but how well his knowledge will penetrate
the clinical reality may be a challenge. It is a paradox in
cancer medicine that favorable survival comes along with
an increasing risk of SPCs, thus expanding the frontier in
the ﬁght against cancer deaths.
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